308 related articles for article (PubMed ID: 11914912)
21. The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo.
Fisher SJ; Swaan PW; Eddington ND
J Pharmacol Exp Ther; 2010 Jan; 332(1):326-33. PubMed ID: 19820208
[TBL] [Abstract][Full Text] [Related]
22. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
24. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.
Ganta S; Devalapally H; Amiji M
J Pharm Sci; 2010 Nov; 99(11):4630-41. PubMed ID: 20845461
[TBL] [Abstract][Full Text] [Related]
25. Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity.
Patel K; Patil A; Mehta M; Gota V; Vavia P
Int J Pharm; 2014 Sep; 472(1-2):214-23. PubMed ID: 24954663
[TBL] [Abstract][Full Text] [Related]
26. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats.
Choi JS; Choi HK; Shin SC
Int J Pharm; 2004 May; 275(1-2):165-70. PubMed ID: 15081147
[TBL] [Abstract][Full Text] [Related]
27. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
[TBL] [Abstract][Full Text] [Related]
28. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
Naito M; Matsuba Y; Sato S; Hirata H; Tsuruo T
Clin Cancer Res; 2002 Feb; 8(2):582-8. PubMed ID: 11839680
[TBL] [Abstract][Full Text] [Related]
29. Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
Wang X; Chen Y; Dahmani FZ; Yin L; Zhou J; Yao J
Biomaterials; 2014 Aug; 35(26):7654-65. PubMed ID: 24927684
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
[TBL] [Abstract][Full Text] [Related]
31. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform.
Choudhury H; Gorain B; Karmakar S; Biswas E; Dey G; Barik R; Mandal M; Pal TK
Int J Pharm; 2014 Jan; 460(1-2):131-43. PubMed ID: 24239580
[TBL] [Abstract][Full Text] [Related]
32. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
[TBL] [Abstract][Full Text] [Related]
33. Enhanced oral bioavailability of docetaxel by coadministration of cyclosporine: quantitation and role of P-glycoprotein.
Chiou WL; Wu TC; Ma C; Jeong HY
J Clin Oncol; 2002 Apr; 20(7):1951-2; author reply 1952. PubMed ID: 11919259
[No Abstract] [Full Text] [Related]
34. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
35. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.
Peltier S; Oger JM; Lagarce F; Couet W; Benoît JP
Pharm Res; 2006 Jun; 23(6):1243-50. PubMed ID: 16715372
[TBL] [Abstract][Full Text] [Related]
36. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
van Asperen J; van Tellingen O; Sparreboom A; Schinkel AH; Borst P; Nooijen WJ; Beijnen JH
Br J Cancer; 1997; 76(9):1181-3. PubMed ID: 9365166
[TBL] [Abstract][Full Text] [Related]
37. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
38. Enhanced bioavailability of paclitaxel by bamboo concentrate administration.
Kang KW; Choi JS
Arch Pharm Res; 2005 Apr; 28(4):469-75. PubMed ID: 15918522
[TBL] [Abstract][Full Text] [Related]
39. Oral delivery of taxanes.
Malingré MM; Beijnen JH; Schellens JH
Invest New Drugs; 2001 May; 19(2):155-62. PubMed ID: 11392449
[TBL] [Abstract][Full Text] [Related]
40. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
